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ABSTRACT 
 
Factors Affecting Parents’ Decisions to Treat Their Children with Autism Spectrum 
Disorder with Complementary and Alternative Treatments. (August 2011) 
Sarah Elizabeth Hall, B.A., Texas A&M University 
Chair of Advisory Committee: Dr. Cynthia Riccio 
 
Autism affects approximately one in 110 children in the United States.  Many 
parents choose to treat their children with autism spectrum disorder (ASD) with 
complementary and alternative (CAM) treatments.  In this study, factors that contribute 
to parents’ decisions to treat their child with ASD with a complementary or alternative 
(CAM) treatment were examined through the use of an online survey.  Invitations to 
participate in the study were sent to approximately 800 support groups for parents of 
children with autism and information from 452 respondents was used in data analysis.  
Information regarding the impact of parental characteristics, children’s behavioral 
symptoms, characteristics of specific CAM treatments, and possible barriers to treatment 
were obtained and analyzed.   
 Overall, the responding parents/guardians were mothers, fathers, and 
grandmothers with a mean age of 41.58.  The majority self-identified as White (86.7%), 
with 41.8% having attained a college education.  The average income of respondents 
was $89,106.66.  100% of the participants in the study indicated they had tried a CAM in 
the past, or were currently using one.   
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 Results indicated a statistically significant relationship between severity of 
symptoms with having tried treatments in the past, and with currently using treatments.  
In addition, several specific treatments that were tried in the past and were currently 
being used were correlated with greater severity of symptoms.  Severity of symptoms 
was not predictive of the total number of CAMs used. Educational level and marital 
status of parents were predictive of CAM use.  In addition, individuals with a graduate 
level degree were more likely to use CAM than those with technical school/some 
college.  Respondents who were married were significantly more likely to use CAMs 
than those who were divorced.  Results indicated that accessibility and acceptance of 
treatments were predictive of CAM use.  Possible barriers to treatment, as well as study 
limitations and implications, are also discussed.  The findings of this study are 
important, as while the use of CAM treatments is growing among the population of 
children with autism, information regarding the reasons parents decide to use CAM 
treatments with their children with autism is relatively sparse. 
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CHAPTER I 
INTRODUCTION  
 Autism affects approximately one in 110 children in the United States (Centers 
for Disease Control and Prevention [CDC], 2009). Autism is a disorder in which the 
classic features are abnormal or impaired development in social interaction and 
communication, in combination with a severely restricted repertoire of activity and 
interests (American Psychiatric Association [APA], 2000).  Children with autism also 
may display degrees of repetitive and stereotyped behaviors (APA, 2000) that are 
manifested in various ways, depending on the child and the level of impairment.   
 Goin-Kochel, Myers, and Mackintosh (2007) quoted Donald Cohen, “When 
there is no cure, there are 1000 treatments” (p. 195); this is particularly true for autism.  
In fact, there is no controversy regarding treatment in the area of developmental 
pediatrics more controversial than treatments for children with autism spectrum 
disorders (ASD; Levy & Hyman, 2005). Due to its chronic nature and lack of a cure, 
ASD have become the focus of several unconventional treatments (American Academy 
of Pediatrics, 2001). While there are many case studies and anecdotal evidence about the 
benefits of different treatments, many of these treatments have not been examined 
experimentally (Campbell, Schopler, Cueva, & Hallin, 1996), and there is little 
information about the frequency of use of these strategies and the characteristics 
associated with their use (Levy, Mandell, Merhar, Ittenbach, & Pinto-Martin, 2003). 
Since autism was first described in the 1940s, there have been numerous theories about  
____________ 
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the etiology of autism and treatments to go with them (Fombonne, 2008). Parents face 
many difficulties in finding an appropriate treatment for their child with ASD. For 
example, when conducting a Google® search with the terms “autism” and “alternative 
medicine,” Zimmer and Molloy (2007) found more than 600,000 sites. It is no wonder 
then that parents have difficulty sorting out legitimate medical information from 
pseudoscience in the mainstream media.  
 Of the numerous types of treatments available for children with autism, many are 
classified as complementary and alternative treatments.  Complementary and alternative 
(CAM) treatments can be used alongside (complementary) and as a substitute 
(alternative) for conventional treatments (Hyman & Levy, 2005). The website of the 
National Center for Complementary and Alternative Medicine 
(http://nccam.nih.gov/health/whatiscam/) gives the following definition of 
complementary and alternative medicine: “CAM is a group of diverse medical and 
health care systems, practices, and products that are not presently considered to be part 
of conventional medicine”. According to NCCAM, conventional medicine is medicine 
practiced by medical doctors and doctors of osteopathy, as well as other related health 
professionals (e.g., psychologists and physical therapists). Many complementary and 
alternative treatments have not been tested through scientific methods, but many families 
still use them (Levy et al., 2003).  
 CAM use is common among children with autism spectrum disorders, and 
caregivers of children with ASDs must sort through a wide variety of treatments 
promoted by various individuals and groups (Challman, 2008; Zimmer, 2011).  Gupta 
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(2010) said that the lack of evidence regarding the biological causes of autism have led 
to greater exploration of complementary and alternative treatments for children with 
ASDs. A number of studies have explored the prevalence of children with ASD using 
complementary and alternative treatments. In a study examining the prevalence of the 
use of different types of treatments with 112 families, 74% were using complementary 
and alternative medicine for their child with ASD (Hanson et al., 2007). Levy et al. 
(2003) found that 31.7 % of the children with autism in their study were currently using 
one or more CAM therapies. Wong and Smith (2006) compared patterns of CAM 
therapy use in children with ASD to children with no ASD. Results indicated that 52% 
of parents of children with an ASD reported using at least one CAM therapy for their 
child, compared to 28% of parents in the control group. Of the therapies used in the ASD 
group, 70% were biologically based (e.g., vitamins, modified diets, etc.) Overall, 75% of 
the parents felt that the CAM therapies were beneficial.  Senel (2009) surveyed 38 
Turkish parents of children with ASD regarding their use of CAM treatments.  Through 
an internet questionnaire, “vitamins and minerals,” “special diet,” “sensory integration,” 
other dietary supplements,” and “chelation” were five treatments that were frequently 
endorsed.  Goin-Kochel et al. (2007) examined the types of therapies parents had tried or 
were currently using with their children with an ASD. While many endorsed 
conventional therapies (such as Applied Behavior Analysis), some alternative treatments 
were endorsed, including auditory integration therapy, chelation therapy, and music 
therapy. Of interest is that 60% of children younger than 5.9 years had tried a gluten-free 
or casein-free diet, as had 56% of children six to 11.9 years. On average, children in the 
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study had tried between seven and nine therapies and were currently using between four 
and six. The authors emphasized that families are using many treatments simultaneously 
for their children with ASD, and some of these treatments are not supported by scientific 
evidence. 
 Despite the high prevalence of CAM therapies used, there is little information 
available about how and why parents make these treatment decisions for their children 
with an ASD (Mandell & Novak, 2005). Levy et al. (2003) examined factors that 
correlated with the use of different types of complementary and alternative medicine in 
children with autism. Data were collected at an autism center that is part of a children’s 
hospital in a large city in the United States. By reviewing 284 charts of children 
suspected of having autism or recently diagnosed with autism, they found that more than 
30% of these children were using some type of CAM, and 9% of the children were using 
a potentially harmful CAM (e.g., cod liver oil, antibiotics, antifungals, chelation 
treatment, withholding immunization). It was found that having another diagnosis in 
addition to autism was a protective factor against CAM use.  Children who had 
previously seen health care providers were more likely to engage in potentially harmful 
CAM use. Levy et al. (2003) suggested that this may be due to several factors. Families 
who have had time to see numerous providers might have been aware of their child’s 
autism for a longer amount of time, and had more time to identify and use CAM 
treatments. The longer families were on a wait list for an appointment, their frustration 
may have increased, leading them to seek out riskier treatments. Longer wait time also 
allows parents more time to seek out information on the internet and connect with other 
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families using CAM. The authors did not examine whether behaviors of the child had an 
impact on CAM use.  
 Nickel (1996) stated, “The search for a magical cure may be one stage in a 
parent’s adjustment to the diagnosis of a developmental disability in his or her child. The 
parent may try controversial treatments as a part of this search” (p. 29). Parents can be 
enticed by promises of a cure, and popular media (e.g., television programs, 
commercials) can be encouraging of untested therapies (Nickel, 1996; Christon, 
Mackintosh, and Myers, 2010). Child characteristics (the severity of the disability, the 
degree of behavior problems) can affect parents’ decisions to try controversial 
treatments. The author also suggests that the growing focus of Americans on personal 
fitness and preventive health care has contributed to the increase in use of certain 
alternative treatments, such as megavitamins and diets. In an unpublished 1995 survey of 
parents of children receiving services from a local autism program, 50% of the children 
were using a nonstandard therapy, and 32% or more had tried two or more nonstandard 
therapies (Nickel, 1996). 
 There also appears to be a possible cultural component to treatment decisions in 
autism. A review of the literature on the cultural factors involved when families make 
treatment decisions for their child with ASD, Mandell and Novak (2005) concluded that 
parents’ beliefs about child development, their personal interpretation of symptoms of 
ASD, its etiology and course, and their experiences with the health system all influence 
treatment decisions. They proposed that symptoms of autism may present differently in 
different cultures, due to genetic or environmental factors; however, evidence for this 
 6 
has been mixed, and there are no studies that look at ethnic differences in the 
presentation of different symptoms of ASD (Mandell & Novak).   
 Norms about child development are shaped by culture, and symptoms that are 
seen as problematic in one culture may not be seen as problematic in another (Daley, 
2004). Therefore, parents from different cultures may interpret the same symptoms 
differently. For example, Asian/Pacific Islander and African-American parents were less 
likely than white parents to agree with their adolescent children’s teachers that the 
adolescent’s behavior could be due to an underlying disorder (Lau et al., 2004). Persons 
from different cultures also may be more likely to notice certain behaviors early on. 
Daley (2004) found that Indian parents were more likely to notice social skills 
weaknesses, while American families are more likely to notice general developmental 
difficulties or regression in language abilities (Coonrod & Stone, 2004). Parents from 
different cultures may value certain abilities more than others (language, social skills), 
and may be more attuned to the skills they favor. In addition, culture is often associated 
with socioeconomic and geographical limitations that can lead to difficulties with 
accessing healthcare (Daley, 2004).   
 Families’ beliefs about the cause of autism also may affect treatment decisions 
(Mandell & Novak, 2005). For example, if parents believe that their child’s autism is 
caused by exposure to heavy metals, they may choose one of the controversial 
treatments aimed at heavy metal detoxification. Also, parents’ understanding of their 
child’s prognosis may affect treatment decisions. If they believe that autism can be 
cured, parents may seek out a treatment that claims the ability to cure autism. If parents 
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believe that autism is chronic, parents may seek out treatments to alleviate symptoms of 
the disorder. Mandell and Novak  suggested that these parents may make the most stable 
treatment decisions. Alternatively, parents who believe autism is chronic and incurable 
may also decide not to try any treatment, and do little or nothing.   
 The interaction between healthcare systems and families also has an effect on 
treatment decisions. There has been some research showing that ethnic minorities have 
different experiences with the healthcare system, especially in obtaining accurate 
diagnoses (Mandell & Novak). In a study examining racial differences at first age of 
diagnosis, on average, African-American children were diagnosed with autism 18 
months later than white children, and required three times the number of visits than 
white children to receive a diagnosis of autism (Mandell, Listerud, Levy, & Pinto-
Martin, 2002).  
 Levy and Hyman (2003) found that Latino children with autism were six times 
more likely than children of other ethnicities to use complementary and alternative 
treatments. Their sample of Latino children was small, but results suggested the need for 
further research in this area; this is the only study specifically looking at the role of 
culture in treatment decisions for ASD (Mandell & Novak). Pachter and Weller (1993) 
examined level of acculturation and compliance with medical therapy in a sample of 
Puerto Rican families with a child with asthma. They found that families who were less 
acculturated tended not to adhere as strictly to conventional treatments prescribed by 
their physicians, suggesting that culture plays an important role in treatment decisions. 
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While more research is needed, it appears that cultural factors may play a role in parents’ 
treatment decisions for their children with autism.  
 Treatment acceptability may also affect parents’ decisions to treat their child with 
an alternative or complementary treatment. Kazdin (1980) conceptualized treatment 
acceptability as judgments of treatments by consumers or potential consumers. In her 
study of treatment acceptability, Carter (2008) examined treatment acceptability through 
the conceptualization of Lennox and Miltenberger (1990), who grouped important 
factors into four categories: efficacy considerations, secondary effects, social/legal 
implications, and practical considerations. Efficacy considerations include motivational 
variables, (which have the potential to increase treatment effectiveness), and treatment 
effectiveness, which is the demonstration of clinically significant change.  
 Secondary effects include side effects, which can be beneficial or detrimental, as 
well as the potential for abuse by those implementing the treatment. Social and legal 
implications include the restrictiveness or intrusiveness of the treatment (i.e., the amount 
of stress placed upon the patient), treatment precedence (the previous known 
effectiveness of a treatment), the social acceptability of the treatment, and the 
understanding of regulatory factors regarding the treatment (e.g., legislation, agency 
regulations, guidelines, etc.). Practical considerations include the competence of staff 
implementing treatments and the cost-effectiveness of the treatment. Carter (2008) 
suggested additional factors to be considered when examining treatment acceptability, 
including that treatment acceptability is not stagnant and can change over time, the 
immediacy of treatment effects, and the influence of the treatment provider on the 
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consumer. Also, Carter suggested that difficulties getting feedback from individuals with 
severe developmental disabilities regarding their acceptance of more restrictive 
treatments can pose a problem in understanding their preferences. 
Purpose of the Study  
 
 Many factors potentially affect parent decisions for treatment for their child with 
an ASD (see Figure 1). Many of these factors, including the impact of child factors (e.g., 
behavioral severity) on their parents’ decision to treat them with a CAM have not been 
examined. The purpose of this study was to examine factors that contribute to parents’ 
decisions to treat their child with ASD using a complementary or alternative treatment. 
Specifically, the research questions are:  
1. Do parents of children with an ASD who exhibit more severe behavioral 
symptoms gravitate toward complementary and alternative (CAM) 
treatments and therapies?  It is hypothesized that parents of children with 
more severe behavioral symptoms will seek out more CAM treatments and 
therapies. 
2. To what extent does demographic information of the parents affect their 
treatment decision for their child with an ASD? It is hypothesized that 
parent characteristics (e.g., marital status, country of origin, length of time 
in the United States, educational level, and employment status) will have an 
impact on their use of CAM. 
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3. Are there specific characteristics of the CAM treatments that impact 
decision-making (e.g., cost, accessibility, the child’s living situation, the 
number of available treatments, treatment acceptability)?   
4. What are some of the barriers to treatment (belief that Autism is/is not 
curable, ease of obtaining information, number of medical professionals 
consulted, and experience with health care system)? 
 
 
 
Figure 1  Factors Affecting Treatment Decisions 
 
Implications for Practice 
There are several reasons why it is important to understand the underlying factors 
that affect why parents of children with autism gravitate toward different types of 
treatments and therapies. Health care providers are increasingly being asked for advice 
and information about CAM treatments (Zimmer & Molloy, 2007).  In a sample of 539 
physicians, Golnik and Ireland (2009) found that 58.9% endorsed encouraging at least 
Treatment 
Decision 
Parent 
Characteristics 
Child 
Characteristics 
Treatment 
Variables 
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one form of CAM treatment for a child with autism.  In general, all types of health care 
providers who might possibly treat a child with autism (e.g., medical doctors, mental 
health professionals, etc.) should be aware of the high prevalence of use of CAM 
treatments among this population, and be prepared to discuss their use with families 
(Hanson et al., 2007). Levy et al. (2003) suggested that doctors be prepared to discuss 
potentially harmful treatments with parents, and even be prepared to negotiate with 
them. For example, if a family wants to treat the child’s autism with vitamins that are 
toxic in high doses, the physician can negotiate with them to lower the dosage. Parents 
who are interested in CAM therapies will often be well-versed in the treatments in which 
they are interested, and doctors should be ready to help them understand the possible 
dangers involved with the treatment, as well as give them a realistic picture of the child’s 
prognosis.   
Definitions 
 1.  Autism Spectrum Disorders (ASD), also known as Pervasive 
Developmental Disorders, “are characterized by severe and pervasive 
impairment in several areas of development: reciprocal social interaction 
skills, communication skills, or the presence of stereotyped behavior, 
interests, and activities.” ASD include Autistic Disorder, Asperger’s 
Disorder, Pervasive Developmental Disorder Not Otherwise Specified, 
Rett’s Disorder, and Childhood Disintegrative Disorder (American 
Psychiatric Association [APA], 2000).   
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2.  Conventional Treatment: medicine practiced by medical doctors and doctors 
 of osteopathy, as well as other related health professionals 
 http://nccam.nih.gov/health/whatiscam/). 
3.  Complementary and Alternative (CAM) Treatment: a group of diverse 
 medical and health care systems, practices, and products that are not presently 
 considered to be part of conventional medicine
 (http://nccam.nih.gov/health/whatiscam/). 
4.  Treatment Acceptability: judgments of treatments by consumers or potential 
 consumers. 
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CHAPTER II 
 
LITERATURE REVIEW 
 
As stated previously, autism affects approximately one in 150 children in the 
United States [Centers for Disease Control and Prevention (CDC), 2007]. The classic 
features are abnormal or impaired development in social interaction and communication, 
in combination with a severely restricted repertoire of activity and interests (American 
Psychiatric Association [APA], 2000).  Children with autism also may display degrees 
of repetitive and stereotyped behaviors (APA, 2000) that are manifested in various ways, 
depending on the child and the level of impairment. The term autism spectrum disorder 
(ASD), also known as pervasive developmental disorder, encompasses five different 
disorders: Autistic Disorder, Asperger’s Disorder, Pervasive Developmental Disorder 
Not Otherwise Specified, Rett’s Disorder, and Childhood Disintegrative Disorder 
(American Psychiatric Association [APA], 2000). It seems that many parents turn to 
complementary and alternative treatments for their children with autism. In one study, 
74% were using complementary and alternative medicine for their child with ASD 
(Hanson et al., 2007). While there are many case studies and anecdotal evidence about 
the benefits of different treatments, most of them have not been tested experimentally, 
and many families still use them (Campbell et al., 1996; Levy et al., 2003). There is also 
little information about the frequency of use of these strategies and the characteristics 
associated with their use (Levy et al., 2003). Complementary and alternative (CAM) 
treatments can be used alongside (complementary) and as a substitute (alternative) for 
conventional treatments (Hyman &Levy, 2005). The website of the National Center for 
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Complementary and Alternative Medicine (NCCAM) gives the following definition of 
complementary and alternative medicine: “CAM is a group of diverse medical and 
health care systems, practices, and products that are not presently considered to be part 
of conventional medicine” (http://nccam.nih.gov/health/whatiscam/). According to 
NCCAM, conventional medicine is medicine practiced by medical doctors and doctors 
of osteopathy, as well as other related health professionals (e.g., psychologists and 
physical therapists). 
Complementary and Alternative Treatments (CAM) 
 
CAM treatments are either biologic or nonbiologic (Levy & Hyman, 2002).  
Based on the organization of Levy and Hyman (2005) and Zimmer and Molloy (2007), 
CAM treatments can be divided into five general categories, with some treatments 
overlapping: gastrointestinal and immune treatments, treatments aimed at modulating 
neurotransmitters and neuropeptides, treatments that target impaired methylation 
capacity, heavy metal treatments, and nonbiological interventions. 
 Gastrointestinal and Immune Therapies 
There are several CAM therapies for children with ASD that target the 
gastrointestinal system, for different reasons. While some studies have shown increased 
prevalence of gastrointestinal (GI) symptoms in children with ASD (Molloy & Manning-
Courtney, 2003), others have shown that GI issues occur no more in the population of 
children with ASD than in other populations (Black, Kaye, & Jick, 2002).  It has also 
been suggested that the onset of GI difficulties coincided with onset of autistic 
symptoms at the time of the administration of the measles, mumps, and rubella vaccine 
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(Wakefield et al., 1998). In Wakefield’s (1998) theory about onset coinciding with 
measles mumps rubella vaccine, the authors concluded after comparing results of 
endoscopies from children with ASDs and typically developing children that GI 
inflammation resulting from viral disease from the vaccine was an etiological factor in 
some cases of autism. This connection with the vaccine was later called into question 
and generally disproven, after the validity of the data supporting this was called into 
question (Zimmer & Molloy, 2007). There have also been several causes posited about 
the relationship between GI symptoms and symptoms of ASD. A higher number of 
persons with autism have increased intestinal permeability, which is called the “leaky 
gut” hypothesis (Levy & Hyman, 2005). This hypothesis is the underlying basis for 
several CAM therapies, including secretin and the gluten-free/casein-free diet.  In 
addition to the theory that the vaccine caused the GI difficulty, others have hypothesized 
the GI tract contribution to symptoms of ASD to overgrowth of neurotoxin-producing 
bacteria (Sandler et al., 2000), dysfunction of secretin or secretin receptors (Horvath & 
Perman, 2002; Horvath, Papadimitriou, Rabsztyn, Drachenberg, & Tildon, 1999), or 
dysfunction of serotonin or serotonin receptors (Fiorica-Howells, Maroteaux, & 
Gershon, 2000). 
 Secretin 
 As a result of the belief that secretin is involved with GI difficulties, use of 
intravenous secretin is one of the most well-studied CAM for ASD, with at least fourteen 
randomized, placebo-controlled trials conducted (Zimmer & Molloy, 2007). Secretin is a 
27 amino-acid polypeptide produced in the intestine that is involved in gastrointestinal 
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function (Williams et al., 2005). Until 1998, it was mainly used diagnostically by 
gastroenterologists during endoscopies to examine pancreatic secretion (Levy & Hyman, 
2005). A case report by Horvath et al. (1998) reported changes in developmental and 
behavioral symptoms in children with ASD after secretin administration, leading to a 
number of studies searching for possible mechanisms of effect.  
Numerous theories have been put forward to explain the possible connection 
between secretin and autistic symptoms. A meta-analysis conducted on trials of secretin 
use in children with autism indicated that no difference existed between the placebo and 
intervention groups (Williams, Wray, & Wheeler, 2005). Sandler (2005) suggested that 
there is a strong placebo effect for receiving intravenous injections of secretin, because 
in many studies improvements in symptoms of ASD were reported in both the treatment 
and control groups. Secretin treatments are very expensive, and also have many possible 
negative side effects, including abdominal cramps, abdominal discomfort, bradycardia, 
diaphoresis, diarrhea, nausea, vomiting, headache, lightheadedness, and hypotension 
(Zimmer & Molloy, 2007). Due to these risk factors and because of the lack of 
demonstrated efficacy in well-designed treatment studies, secretin is not recommended 
as a treatment for autism (Williams et al.; Zimmer & Molloy). 
 Gluten-free/Casein-free Diet 
 Levy and Hyman (2003) found that approximately 15% of children with an ASD 
follow a gluten-free/casein-free (GFCF) diet. The popularity of this diet may be due to a 
number of factors: it is presumed to be healthy, it is typically presented in a way that 
suggests a rapid response, and it is noninvasive (Levy & Hyman, 2005). This therapy is 
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also based on the “leaky gut” hypothesis, suggesting that children with autism cannot 
completely break down certain proteins (in this case, gluten and casein), and therefore 
absorb peptide fragments (Levy & Hyman, 2005).  Peptides formed from the breakdown 
of milk and wheat products can be absorbed across the more permeable GI tract, having 
and opioid effect on the brain and leading to symptoms of ASD (Reichelt, Knivsberg, 
Lind, & Nodland, 1991; Shattock, Kennedy, Rowell, & Berney, 1990). Some studies 
have shown that eliminating gluten and casein from the diet may improve behavioral 
symptoms in children with autism. A randomized, single-blind trial of gluten and casein 
elimination demonstrated improvements in an overall score that encompassed nonverbal 
and verbal communication, behavior in learning situations, sharing of emotions, anxiety, 
rigidity, and peculiarity; no improvements in linguistic, cognitive, or motor abilities 
were evident (Knivsberg, Reichelt, Hoien, & Nodland, 2002). Limitations of the study 
included its relatively small sample size. Further, it did not control for other behavioral 
interventions or medications that may have contributed to the positive effects observed. 
It was suggested that the structure imposed on the household by following the diet, as 
well as behavioral therapies not accounted for, could be responsible for the promising 
results. Another trial of the GFCF diet failed to demonstrate differences in both language 
and behavior as a result of the intervention (Elder et al., 2006). No studies assessing the 
safety of GFCF diets have been completed (Zimmer & Molloy); however, there are 
several studies ongoing in the U. S. that will add to the research base with regard to 
whether this diet has therapeutic value for children with ASD. At the same time, it is 
worthy of note that many children with ASD have limited diets based on their sensory 
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aversions to different foods; further restricting their diet by eliminating milk products 
could be detrimental to their overall health (Levy & Hyman, 2005). In fact, one study 
has suggested that the GFCF diet can lead to loss of bone density (Hediger et al., 2008). 
Arnold, Hyman, Mooney, and Kirby (2003) found that children with autism on restricted 
diets had an increased prevalence of amino acid deficiencies and lower levels of 
essential acids than children with autism who were not on restricted diets. They 
suggested that more research be conducted to investigate the extent to which special 
diets possibly harm developing brains through protein malnutrition. Overall, while the 
GFCF diet may in the future be proven to have benefits for certain populations of 
children with ASD with some specific certain set of symptoms, current literature does 
not support or refute claims of its success in the general press (Levy & Hyman, 2005).   
 Specific Carbohydrate Diet (SCD) 
 The Specific Carbohydrate Diet (SCD) is also based on the assumption that 
children with ASD experience some type of GI dysfunction, usually associated with 
increased permeability of the intestines and microbial imbalances.  The SCD aims to 
give children carbohydrates of smaller molecular size so that they do not have to be 
broken down in the body (Gottschall, 2004, as cited in Levy & Hyman, 2005). The SCD 
was initially developed for people with celiac disease (Levy & Hyman, 2005). There are 
no research studies of the efficacy of this diet in the treatment of ASD (Levy & Hyman, 
2005); as with the GFCF diet, there is concern that the SCD might lead to nutritional 
deficiency.   
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 Digestive Enzymes and Probiotics 
 The use of digestive enzymes and probiotics in children with ASD is also related 
to the “leaky gut” hypothesis (Levy & Hyman, 2005).  Digestive enzymes are 
hypothesized to break down food products into small, nontoxic particles (Zimmer & 
Molloy) and remove the toxic particles from the gastrointestinal tract (Levy & Hyman, 
2005). According to Zimmer and Molloy, probiotics “are products containing microflora 
in amounts sufficient to alter intestinal flora with the purpose of sustained health 
benefits” (p. 270). In an open-label trial of digestive enzymes combined with probiotics, 
a few children with an ASD were reported to show some behavior improvements 
(Brudnak et al. 2002). In this trial, 40% of the subjects were already on a GFCF diet, and 
raters of outcome measures were not blinded to the treatment condition. Despite the lack 
of evidence for their use, digestive enzymes are frequently used (Levy & Hyman, 2005). 
Immune Therapies 
Antifungals and a yeast-free diet have been suggested as a treatment for colonic 
yeast overgrowth in individuals with ASD (Levy & Hyman, 2005). Colonic yeast 
overgrowth has been suggested as a possible contributor to symptoms of ASD through 
its affect on immune system function; however, colonic yeast overgrowth in individuals 
with ASD has not been substantiated in a peer-reviewed medical journal, and there are 
no published therapeutic trials of the use of oral antifungal agents in this population 
(Levy & Hyman, 2008; Zimmer & Molloy). Still, use of medication to treat yeast 
overgrowth in children with autism remains popular (Levy & Hyman, 2008). It is 
thought that yeast overgrowth is due to intestinal dysbiosis or immune factors unique to 
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autism (Levy & Hyman, 2008). It should be remembered that the chronic use of oral 
antifungal agents can cause hepatoxicity and requires close monitoring (Levy & Hyman, 
2005; Zimmer & Molloy).  
Antibiotics 
There is growing evidence that there is some type of association between the 
immune system and ASDs, although no specific pattern of dysfunction has been 
identified (Zimmer & Molloy). Sweeten et al. (2003) found that children with an ASD 
were more likely to have a family history positive for autoimmune disease. Identified 
possibilities included abnormalities in cytokines (Croonenberghs, Bosmans, Deboutte, 
Kenis, & Maes, 2002; Gupta, Aggarwal, Rashanravan, & Lee, 1998; Jyonouchi, Sun, & 
Le, 2001), autoantibodies to neuronal elements (Connolly et al., 1999), and cell-
mediated response and allergic immune response (Gupta, Aggarwal, & Heads, 1996). 
Related to this, Sandler et al. (2000) proposed that autistic symptoms are exacerbated by 
the increased use of antibiotics. The hypothesis was that repeated use of antiobiotics 
leads to gut bacterial overgrowth and colonization by “neurotoxic” bacteria, which cause 
an autistic regression.  To test this hypothesis, Sandler et al. (2000) gave oral 
vancomycin (an antibiotic) to 11 children with a recent diagnosis of autism who had 
used antibiotics within two months of symptoms appearing and also had diarrhea. 
Improvement in symptoms of autism was noted and waned after treatment was 
withdrawn.  While they did not say that this was a useful treatment for ASD, the authors 
presented this as evidence of the interaction of antibiotics and the brain in some children 
with ASD. D-Cycloserine is an antiobiotic that has been proposed as a treatment for 
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autism.  It has shown to reduce disruptive symptoms in adults with schizophrenia when 
administered in conjunction with a neuroleptic medication (Goff et al., 1999), and a 
small uncontrolled study showed some reduced social withdrawal and increased social 
responsiveness as measured by the Aberrant Behavior Checklist (Posey et al., 2004). 
More research is needed to determine its usefulness in children with autism.  
 Intravenous Immunoglobulin (IVIG) 
  Intravenous Immunoglobulin (IVIG) is an expensive therapy that involves 
intravenous infusion and has many possible adverse side effects (Zimmer & Molloy, 
2007). It has been used as a therapy for several immune disorders (Gupta et al., 1996), 
and it has been given to children with autism to treat various immune system deficits 
(Levy & Hyman, 2005). Some success was shown in a study by Gupta et al. (1996), 
where ten children with autism showed improvements after six months of treatment. 
Possible side effects include renal tubular acidosis, thromboembolic events, aseptic 
meningitis, rash, and blood-borne infection (Levy & Hyman 2005).    
 Therapies Targeting Neurotransmitters and Neuropeptides  
It has also been suggested that multiple neurotransmitter systems are 
dysfunctional in individuals with ASD, due to observed clinical features of many 
individuals with autism (i.e., larger head circumference, larger brain volume, seizures, 
irregular sleep patterns, and mental retardation (Polleux & Lauder, 2004). Specific 
systems with the most evidence for abnormalities are the y-aminobutyric acid (GABA)-
ergic system, glutaminergic system, and serotonergic system (Mulder et al., 2004; 
Polleux & Lauder, 2004; Spivak et al., 2004). The nature of these abnormalities is 
 22 
generally unclear and undergoing continued study. For example, in the serotonergic 
system, some studies have suggested that autism is associated with hyperserotonemia 
(Anderson, Horne, Chatterjee, & Cohen, 1990; Mulder et al., 2004), while Spivak et al. 
(2004) suggested that autism is associated with hyposerotonemia. Medications that act 
on these transmitters (e.g., resperidone, fluoxetine, and fluvoxamine) have shown some 
benefits in some individuals with ASD; this has given further reason to examine the 
possible role of neurotransmitter systems in autism (Zimmer & Molloy).   
Neuromodulators 
 Dimethylglycine (DMG) is a commonly used dietary supplement that has been 
reported to benefit children with autism (Kern et al., 2001; Bolman & Richmond, 1999; 
Levy & Hyman, 2008). It is sold in health food stores as a supplement for athletes as 
well as individuals with ASD (Kern et al., 2001). Bolman and Richmond hypothesized 
that DMG might exert influence on the balance of inhibitory versus excitatory 
neurotransmission, because of its potential ability to cross the blood-brain barrier. Many 
parents of children with autism believe that supplementing their child’s diet with DMG 
improves their child’s symptoms (Kern et al., 2001). It is also believed by some that 
DMG is a cure for many illnesses (including cancer and hepatitis), but there is little 
scientific evidence to support these claims. Two double-blind, placebo-controlled trials 
in children with autism produced negative results (Bolman & Richmond, 1999; Kern et 
al. 2001). Even in light of these results, DMG is promoted as a therapy for autism by 
many alternative medical practitioners (Zimmer & Molloy). A possible negative side 
effect of fatty infiltration of the liver has been shown in long-term use of pangamic acid, 
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which is a closely-related compound to DMG (Ziemlanski, Wielgus-Serafinska, 
Panczenko-Kresowska, & Zelakiewicz, 1984). 
 Polyunsaturated Omega-3 Fatty Acids 
 Problems with the metabolism of fatty acids may have important biological and 
etiological significance in autism (Bu et al., 2006). Polyunsaturated fatty acids must be 
taken in through the diet and are essential for normal brain development and functioning 
(Amminger et al., 2007; Horrobin, Glen, & Vaddadi, 1994; Levy & Hyman, 2008). They 
are naturally occurring lipids that become part of phospholipids and have many neural 
functions as parts of neuronal cell membranes, such as cell signaling, neurotransmission, 
and second-messaging (Bennett & Horrobin, 2000; Horrobin & Bennett, 1999; Horrobin 
et al., 1994). Some studies have shown that individuals with ASD have less 
polyunsaturated omega-3 fatty acids in their red blood cell membranes and plasma (Bell 
et al., 2004; Vancassel et al., 2001), and one study has shown a slight increase in some 
minor fatty acids of children with autism (Bu et al., 2006). Abnormalities in the fatty 
acid design of phospholipids, which are the main elements of cell membranes, have been 
discovered in individuals with neurodevelopmental disorders (Bu et al., 2006). For this 
reason, Omega-3 fatty acid supplements (also known as fish oil, cod liver oil, evening 
primrose oil, and flax oil) are a type of nutritional supplement sometimes used in 
treatment of ASD. Clinical trials of use in treating other disorders have shown promise 
(Zimmer & Molloy, 2007), and a randomized double-blind, placebo-controlled trial 
using a similar supplement produced improvements in hyperactivity and stereotypy 
(Amminger et al., 2007). Despite these positive effects, this study should be replicated 
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with a larger sample size and stronger statistical analysis (Zimmer & Molloy). Common 
side effects of Omega-3 supplements include increased belching, fishy odor, skin rash, 
abdominal distention, diarrhea, increased risk of nosebleed, and easy bruising 
(Amminger et al.; Zimmer & Molloy). Overall, there are few research studies that 
support the practice (Levy & Hyman, 2005).  
 L-Carnosine 
  L-Carnosine is a dipeptide hypothesized to act as a general neuroprotective 
agent or modulator of GABA activity in the brain (Zimmer & Molloy, 2007; Chez et al., 
2002; Zimmer & Molloy). GABA is an inhibitory neurotransmitter located in the 
cerebral cortex (Levy & Hyman, 2005),  In a randomized, placebo-controlled trial, 
children treated with an oral supplement of L-Carnosine showed improvement on the 
Gilliam Autism Rating Scale and the Receptive One-Word Picture Vocabulary test, as 
compared with control subjects (Chez et al., 2002). While these results appear 
promising, Levy and Hyman (2005) pointed out that receptive language improvements 
could be due to maturation, educational interventions, placebo effect, and other possible 
confounds that were not addressed in the research design. Chez et al. (2002) 
acknowledged that while the mechanism of action is not well understood, L-Carnosine 
may work by enhancing neurologic functioning. No side effects except for occasional 
hyperactivity were reported by parents of children in Chez’ study. 
 Tryptophan and Tyrosine 
  As mentioned previously, there have been a number of studies documenting 
abnormalities in the serotonergic system in individuals with ASD. Tryptophan is an 
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essential amino acid precursor to serotonin (Levy & Hyman, 2005; Zimmer & Molloy) 
that is sometimes used as a treatment for children with ASD.  Some believe that 
supplementing tryptophan in children with ASD is a safer option than giving them a 
drug that would affect serotonin release or reuptake inhibition (Levy & Hyman, 2005). 
In their case study of an adult woman with autism, McDougle et al. (1993) suggested 
that dietary tryptophan depletion increased symptoms of ASD, and posited that this is 
due to reducing the supply of serotonin in the brain. Hanley, Stahl, and Freedman (1977) 
demonstrated that an oral dose of tryptophan increased excretion of urinary metabolites 
of serotonin production, but found no correlation to change in symptoms of ASD. In 
their examination of the plasma amino acid profiles of children with ASD, Arnold et al. 
(2003) found that children with autism on restricted diets had lower plasma amino acid 
levels of tryptophan and tyrosine, which is a dietary precursor to dopamine, 
norepinephrine, and epinephrine. Because of this, some argue for tyrosine 
supplementation in children with autism; however, no studies have evaluated its safety 
or effectiveness (Zimmer & Molloy).    
 Naltrexone 
  Naltrexone is an opioid agonist that is hypothesized to work by lowering high β-
endorphin levels (Bouvard et al., 1995; Cazzullo et al., 1999; Gillberg, 1995; Willemsen-
Swinkels, Buitelaar, Weijnen, Thijssen, & Van Engeland, 1996). It is theorized by some 
that autism is associated with hypersecretion of brain opioids, including β-endorphins 
(Feldman, Kolmen, and Gonzaga, 1999; Panksepp & Lensing, 1991). It is also suggested 
that highly elevated levels of brain opioids are responsible for self-injurious behavior in 
 26 
autism (Willemsen-Swinkels et al., 1996). Naltrexone was used in a number of studies of 
individuals with autism to reduce hyperactivity, self-injurious behavior, and 
stereotypical and impulsive behavior (Campbell et al., 1993; Herman, Hammock, 
Arthur-Smith, Kuehl, & Appelgate 1989; Kolmen, Feldman, Handen, & Janosky, 1997; 
Panksepp & Lensing, 1991; Willemsen-Swinkels et al., 1996). In a randomized, double-
blind, placebo controlled study by Feldman et al. (1999), naltrexone was not found to 
improve communication skills in children with autism. Bouvard et al. (1995) suggested 
that naltrexone only has therapeutic effects for a subgroup of children with autism who 
have certain plasma abnormalities. Possible side effects of naltrexone include excessive 
sedation, decreased appetite, and vomiting (Campbell et al., 1993). More research is 
necessary to establish naltrexone as a positive treatment for symptoms of autism 
(Gillberg, 1995; Campbell et al., 1993). 
S-adenosylmethionine 
S-adenosylmethionine (SAM-e) is involved in many biological reactions, 
including the methylation of DNA, phospholipids, and synthesis of several 
neurotransmitters (Zimmer & Molloy).  It has been shown in some studies to be as 
effective as tricyclic antidepressants in clinical trials of depression, and in other studies 
has shown results equal to placebo (Zimmer & Molloy). There are no published studies 
of SAM-e in treatment of autism. 
Hyperbaric Oxygen Therapy (HBOT) 
 Hyperbaric Oxygen Therapy (HBOT) is another alternative treatment that is 
being explored in children with autism (Levy & Hyman, 2008; Rossignol, Rossignol, 
 27 
James, Melnyk, & Mumper, 2007). It provides pressurized oxygen at high pressures; 
possible side effects include ear pain and seizures. It is thought to increase blood flow 
and oxygen to the brain and decrease inflammation, and is currently being investigated 
in treating disorders of the central nervous system (Levy & Hyman, 2008). Because of 
its ability to reduce oxidative stress and inflammation, it is being explored as a treatment 
for autism (Rossignol et al., 2007). In an open clinical trial by Rossignol et al. (2007), 
parents of 18 children with autism treated with HBOT reported improvements in 
symptoms of autism, but subjective data and potential confounds affect the 
interpretability of these results (Levy & Hyman, 2008). There are currently no 
randomized controlled trials of HBOT in the treatment of symptoms of ASD available 
(Levy & Hyman, 2008).  
Other Natural Supplements 
 Vitamin C is involved in the conversion of tryptophan to serotonin and tyrosine 
to dopamine; it also is a regulator of cellular immune function, and therefore might be 
useful in the treatment of ASD (Levy & Hyman, 2005). It is usually not used in an 
isolated fashion; rather, it is added to vitamin mixtures taken by children with ASD 
(Levy & Hyman, 2008). In a double-blind, placebo-controlled trial of children and 
adolescents with autism (Dolske, Spollen, McKay, Lancashire, & Tolbert, 1993), 
reduction of symptoms was noted in the treatment group, but the mechanism through 
which this worked was not clear. The study has not been replicated and Vitamin C has 
not gained popularity as a treatment for children with ASD (Levy & Hyman, 2008).   
 28 
 Melatonin is a hormone derived from serotonin that is stimulated by darkness 
and is involved in the regulation of the circadian rhythm (Brzezinski, 1997; Melke et al., 
2008). It is available over the counter, and is popular among parents of children with 
ASD for regulating their children’s sleep problems (Zimmer & Molloy). Children with 
ASD have been shown to have low levels of melatonin, the reason for which is unknown 
(Melke et al.). From their study, Melke et al. concluded that low melatonin level is a risk 
factor for ASD. In a small, randomized, placebo-controlled double-blind crossover trial 
of melatonin, the authors found significantly reduced sleep latency, a reduced number of 
night wakings, and an increased overall sleep time in children with ASD (Garstang & 
Wallis, 2006). In their review of melatonin treatment of children with 
neurodevelopmental disabilities and sleep difficulties, Phillips and Appleton (2004) 
concluded that melatonin improves sleep latency in this population. The studies included 
in the review were all randomized, double-blind, placebo controlled, crossover trials 
with a small sample size. Using parental report as an indicator of children’s response to 
treatment, Andersen et al. (2008) concluded that melatonin was a safe and well-tolerated 
treatment of sleep-onset insomnia and sleep-maintenance insomnia in a sample of 107 
children. Although there are few randomized clinical trials of melatonin for disturbed 
sleep in children with neurodevelopmental disabilities, it is still commonly prescribed 
(Phillips & Appleton). 
 St. John’s wort is a plant extract often used for depression because it is thought to 
contain substances that inhibit the reuptake of dopamine, serotonin, and norepinephrine 
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(Charrois, Sadler, & Vohra, 2007; Zimmer & Molly). There are no published clinical 
trials regarding use of St. John’s wort in the treatment of autism (Zimmer & Molloy).   
Nutritional Supplements Targeting Impaired Methylation Capacity 
Vitamin B12 
 James et al. (2004) noted in their study that abnormalities exist in the methionine 
cycle in autistic individuals. Methionine is an amino acid important in many cellular 
processes, and it is hypothesized that abnormalities in its vitamin B12 – dependent cycle 
could lead to altered neurotransmission and cell signaling and maladaptive immune 
responses (James et al., 2004; Zimmer & Molloy). Because of this, vitamin B12 is also 
currently being explored as a possible treatment for ASD (Zimmer & Molloy).  
Glutathione 
 Another alternative treatment for autism is glutathione, an antioxidant produced 
as a result of abnormalities in the methionine cycle that was demonstrated to be reduced 
in levels in the serum of persons with autism (James et al., 2004). This has lead to 
increased use of glutathione supplement as a treatment for autism, where it is 
administered intravenously or through a patch. According to Zimmer and Molloy, there 
is no information available regarding the safety or efficacy of this treatment, and there is 
not enough information about this treatment and its side effects in the treatment of 
children with autism.  
Vitamin B6 (pyridoxine) and Magnesium 
 The combination of vitamin B6 (pyridoxine) and magnesium has also used as 
alternative treatment for symptoms of autism for more than twenty years (Levy & 
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Hyman, 2008). This became popular in the 1960s after speech and language 
improvements were reported (Nye & Brice, 2005). Side effects from large doses of 
vitamin B6 (irritability, hypersensitivity to sound, enuresis) are countered with doses of 
magnesium (Mg; Rimland, Callaway, & Dreyfus, 1978). Overall, results have been 
mixed as to the benefit of megadoses of vitamin B6 and magnesium in children with 
autism, with some studies showing promising results (Martineau, Barthelemy, Garreau, 
& Lelord, 1985; Rimland et al. 1978) and others showing no improvement in ASD 
symptoms (Findling et al. 1997). Findling et al. suggested that placebo effects may play 
a role in results of studies of high doses of B6 and magnesium in children with autism. 
Negative side effects include peripheral neuropathy, photosensitivity, nausea, vomiting, 
abdominal pain, cardiovascular effects, sweating, flushing, and central nervous system 
effects (Zimmer & Molloy, 2007). In their review of studies examining the effects of 
vitamin B6-magnesium treatments in autism, Nye and Brice (2005) concluded that there 
is currently not enough evidence to recommend the use of this treatment in autism. 
Folic Acid 
 Folic acid is also given as a multivitamin to address symptoms of ASD (Levy & 
Hyman, 2005). Like vitamin B12, glutathione, B6 and magnesium, folic acid is thought 
to play a role in methylation reactions (James et al., 2006). It has also been hypothesized 
that exposure to toxic agents that lead to oxidative stress can cause neuron damage and 
lead to regression seen in some children with autism (Kern & Jones, 2006). A trial of 
folinic acid and other supplements was thought to play a role in normalizing metabolic 
imbalance in children with autism, but clinical outcome data were not reported (James et 
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al., 2004). Also, folate abnormalities were found in a small group of children diagnosed 
with an ASD, and the authors suggested that children with autism and other 
developmental difficulties may have central nervous system folate abnormalities 
(Moretti et al., 2008). There are currently no randomized controlled treatment trials in 
the literature, and further study is needed (Levy & Hyman, 2008). 
 Heavy Metal Treatments 
Some individuals believe that children with autism have a weakened ability to 
detoxify their bodies of heavy metals, and that they require metabolic therapies (Zimmer 
& Molloy, 2007). These individuals base their beliefs on an article by Hornig, Chian, 
and Lipkin (2004), that showed that mice with a genetic predisposition to be particularly 
sensitive to the effects of mercury demonstrated developmental delays and decreased 
socialization after being exposed to mercury. Although there are few peer-reviewed 
studies of the metabolism of heavy metals in children with ASD, much debate has been 
stimulated in academic circles as well as the general population about the safety of 
mercury/thimerosal in vaccines (Zimmer & Molloy). Thimerosal is a mercury-
containing preservative that has been used in vaccines since the 1930s (Hviid, Stellfeld, 
Wohlfahrt, & Melbye, 2003; Madsen et al., 2003). It was discontinued from use in 
vaccines in the United States in 2001, but autism rates have continued to rise steadily 
(Fombonne, 2008). Contrary to popular belief, there is strong evidence suggesting that 
mercury or thimerosal in vaccines does not cause autism (Andrews et al., 2004; Hviid et 
al., 2003; Madsen et al., 2003; Fombonne, 2008).   
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Metallothionein 
 Metallothionein dysfunction is one theory of difficulty with heavy metal 
detoxification in children with autism. Metallothioneins are cellular proteins that 
neutralize harmful influences of exposure to toxic metals like mercury, zinc, and copper 
(Zimmer & Molloy, 2007; Russo, 2008). One study has shown high levels of anti-
metallothionein antibodies in families of children with autism, but concluded that the 
presence of the antibodies was not a cause of autism, and might result from immune 
systems difficulties seen in other children with autism (Russo, 2008). Treatment involves 
giving the patient a cocktail containing the amino acid precursors to metallothionein, as 
well as selenium and glutathione, which are believed to be diminished when the body 
deals with a higher heavy-metal burden. Trials examining the benefits and risks of this 
treatment have not been published. (Zimmer and Molloy, 2007).   
Chelation 
 Another therapy intended to remove heavy-metals from the body is chelation 
therapy. Designed to be used after acute exposure to a heavy metal, chelation agents 
[dimercaptosuccinic acid (DMSA) and edentate calcium disodium (CaEDTA)] pull 
heavy metals from body tissues that are excreted through urine (Zimmer & Molloy). 
Chelation therapy is untested in children with autism (Sinha et al.ₐ, 2006; Zimmer & 
Molloy) and has many common adverse side effects, including rash, diarrhea, nausea, 
vomiting, and increased liver function tests (Zimmer & Molloy). Chemicals used for 
chelation have not been approved by the Food and Drug Administration for treatment of 
autism (Levy & Hyman, 2005). Other dangerous effects that have been reported include 
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hematological, renal, and liver toxicity (Levy & Hyman, 2005). Deaths of children have 
been reported during treatment, making this a dangerous treatment with little evidence of 
benefits (Centers for Disease Control and Prevention, 2006). 
 Nonbiological Treatments 
Auditory Integration Training 
  Behaviors and responses can be altered through nonbiological interventions, 
because experiences early in life can alter the neural composition of the brain (Levy & 
Hyman, 2005).  Currently, most nonbiological CAM therapies cannot be explained by 
present understanding of the functioning of the brain (Levy & Hyman, 2005). For 
example, heightened sensitivities to sounds and difficulties with auditory perceptions are 
common symptoms in children with autism (Levy & Hyman, 2005).  Zimmer and 
Molloy (p. 278) defined Auditory Integration Training (AIT) as “…a therapy in which 
children are screened for sound sensitivities and then delivered a tailored program of 
auditory input that filters out the sound frequencies to which they are sensitive.” It is 
intended to “retrain” the ear through repeat exposure to altered sounds (Levy & Hyman, 
2002; Levy & Hyman, 2005). Therapy sessions take place over a number of months and 
can be expensive (Zimmer and Molloy). Supporters claim that benefits of AIT include 
improved attention, improved auditory processing, decreased irritability, reduced 
lethargy, improved expressive language, and improved auditory comprehension 
(American Academy of Pediatrics, 1998). Reviews of the literature on auditory 
integration training revealed studies that did not follow strict experimental guidelines 
and had varied results (American Academy of Pediatrics, 1998; Sinha, Silove, Wheeler, 
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& Williams, 2004). Overall, the reviewers concluded that not enough evidence exists to 
recommend this as a therapy for children with autism (American Academy of Pediatrics, 
1998; Sinha et al., 2004).     
 Sensory Integration Therapy 
 Sensory integration therapy is intended to address the abnormal responses to 
typical stimuli displayed by some children with ASDs. It involves exposing the child to 
different sensory-based experiences, such as swinging, joint compressions, holding, 
brushing, and squeezing (Zimmer & Molloy). There are few well-designed clinical trials 
examining sensory integration therapy (Zimmer & Molloy).     
 Massage Therapy 
  Field et al. (1997) suggested that massage therapy may improve the attention of 
children with autism.  In their study, children with autism showed less stereotypical 
behaviors (as measured by the Autism Behavior Checklist) and showed improved social 
relating (as measured by the Early Social Communicating Scales) after a month of twice 
weekly 20-minute massages conducted by massage therapists. Massage therapy has also 
been examined through a clinical trial involving 3- to 6- year olds with an ASD. Parents 
were trained by a massage therapist and delivered a massage 15 minutes prior to bedtime 
(Escalona, Field, Singer-Strunck, Cullen, & Hartshorn, 2001). The intervention group 
displayed fewer stereotypic behaviors, improvement in on-task behaviors, fewer sleep 
problems, and improved social abilities. Massage therapy in children with autism is an 
area in need of further study (Zimmer & Molloy, 2007). Hartshorn et al. suggested that a 
similar treatment, called creative movement therapy, that is also touted to improve the 
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attention and behavior of children with autism. In this study, children with autism aged 3 
to 7 years were led through different movements by a therapist. Movements included 
jumping in and out of hoops and moving through an obstacle course of different gym 
mats. After two months of twice-weekly movement therapy sessions, the children 
showed improvement in response to touch, more on-task behavior, less time wandering, 
and improved compliance with the teacher (Hartshorn et al., 2001). 
Craniosacral Manipulation 
Craniosacral manipulation is a form of therapeutic touch performed by 
chiropractors, physical therapists, and occupational therapists who are trained in its use 
(Levy & Hyman, 2002). The therapist is believed to be able to sense the fluid waves of 
spinal fluid, and applies touch to manipulate these waves (Levy & Hyman, 2005; 
Zimmer & Molloy). There is no evidence that humans can detect through touch changes 
in spinal fluid pressure at the skin surface (Moran & Gibbons, 2001). While there are no 
controlled studies evaluating this therapy (Levy & Hyman, 2008; Zimmer & Molloy), 
therapeutic touch is often used as part of the overall sensory program in academic 
settings and it is possible that therapeutic touch as well as circumstances surrounding the 
therapy (e.g., a relaxing atmosphere) might produce changes in behavior (Levy & 
Hyman, 2005).   
 Facilitated Communication 
 Facilitated communication was designed to allow individuals with severe 
disabilities in motor skills to communicate with a typewriter or other communication 
device (Zimmer & Molloy).  Because motor skills deficits have been observed in some 
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children with autism, this method was put forward to assist these children in 
communicating. The method involves another person (the facilitator) who supports the 
child’s hand to allow him or her more ease in choosing letters on the communication 
device. Several studies examining the influence of the facilitator on the child’s 
communication (i.e., Eberlin, McConnachie, Ibel, & Volpe, 1993; Regal, Rooney, & 
Wandas, 1994) found that children with autism and other developmentally disabled 
individuals were unable to answer questions unless the facilitator knew the answer 
(Zimmer & Molloy). In his review of studies on facilitated communication, Mostert 
(2001) concluded that this therapy is most likely to be confounded by the subconscious 
direction of the facilitator, and does not show true communication on the part of the 
individual. The American Academy of Pediatrics (1998) stated that current research does 
not support claims that facilitated communication works, and should not be used except 
in research. 
 Music Therapy 
  Music therapy involves using music to encourage the participant to take part in a 
relationship-focused exchange (Wigram & Gold, 2006). Initiating and sustaining joint 
attention and reciprocity are clear deficits in children with autism (Maestro et al., 2002), 
and initiating and sustaining joint attention is a primary therapeutic goal in music 
therapy (Wigram & Gold, 2005). A few non-experimental studies have examined music 
therapy with children with ASDs (i.e., Edgerton, 1994) and have reported an increase in 
communication and affecting relationship patterns. A review of studies of music therapy 
(Whipple, 2004) showed mixed results, and questionable designs (Wigram & Gold, 
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2005). No studies with control groups or experimental designs have been conducted 
(Zimmer & Molloy). While not directly a form of music therapy, interactive metronome 
is a theoretical treatment where a musical metronome is used to alter the timing of 
information presented to children to enhance their concentration.  No studies have been 
published examining this treatment (Levy & Hyman, 2002). 
 Behavioral Optometry 
  Because many children with autism display stereotyped behaviors involving 
vision (close visual inspection of items, examining through peripheral field of vision) the 
use of prism lenses has been reported to improve behavior symptoms in children with 
autism (Kaplan, Edelson, & Seip, 1998). In their study, 18 children with autism showed 
a decrease in behavior problems after wearing ambient prism lenses for two months. 
Levy and Hyman (2005) classified this as a type of “behavioral optometry.”  Due to the 
lack of peer-reviewed literature on this topic (Levy & Hyman, 2005), the American 
Academy of Pediatrics (1998) does not recommend any type of optometric therapy for 
children with disabilities.   
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CHAPTER III 
METHODS 
The purpose of this study was to examine factors that contribute to parents’ 
decisions to treat their child with ASD with a complementary or alternative (CAM) 
treatment. The study used an electronic survey approach to gain information from 
parents/guardians of individuals with ASD related to CAM.   
Participants 
Data for this study was collected from parents of children with an autism 
spectrum disorder.  The survey was made available online via SurveyMonkey® 
(http://www.surveymonkey.com/) after obtaining approval by the Institutional Review 
Board.  Email invitations to participate were then sent to approximately 800 support 
groups for parents of children with autism.  Email addresses were obtained by searching 
for parent support groups on the websites autismspeaks.org and autism-society.org.  
Because only those parents/guardians who have access and use online resources could 
participate, there is selection bias in the sample and there is no means of determining 
response rate.  In total, 453 responses were collected; one respondent indicated he/she 
was the child with an ASD and their data was excluded; this resulted in 452 usable 
surveys.  Overall, the responding parents/guardians were mothers, fathers, and 
grandmothers.  The majority self-identified as White (86.7%), with a majority having 
attained a college education (41.8%).  The mean age of respondents was 41.58 (SD= 
8.07), and the mean income was $89,106.66 (SD = $61601.88).  Additional demographic 
information is provided in Table 1. 
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Table 1  Study Participants (N=452) 
 
 Frequencies Percent 
Relationship to Child   
Mother 413 91.4 
Father 33 7.3 
Grandmother 5 1.1 
Other 1 .2 
No response 0 0 
   
Marital Status   
Married 384 85 
Single 16 3.5 
Widowed 9 2 
Divorced 40 8.8 
No response 3 .7 
   
Ethnicity   
White 392 86.7 
Black or African American 20 4.4 
American Indian/Alaskan Native 1 .2 
Asian 8 1.8 
Hispanic or Latino 16 3.5 
Biracial 5 1.1 
Other 6 1.3 
No Response 4 .9 
   
Number of children in family   
One 78 17.3 
Two 226 50 
Three 92 20.4 
Four 33 7.3 
Five 11 2.4 
Six 7 .9 
Eight 1 .2 
Nine 1 .2 
No Response 6 1.3 
   
Country of Birth   
United States 416 92 
Germany 5 1.1 
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Table 1, Continued 
   
 Frequencies Percent 
Canada 4 .9 
United Kingdom 5 1.1 
Colombia 2 .4 
Ethiopia 1 .2 
Jamaica 1 .2 
Cuba 1 .2 
Argentina 2 .4 
India 1 .2 
Italy 1 .2 
Mexico 1 .2 
Venezuela 1 .2 
Japan 1 .2 
Indonesia 1 .2 
Panama 1 .2 
No Response 8 1.8 
   
Country lived in majority of life   
United States 419 92.7 
Canada 3 .7 
Germany 2 .4 
United Kingdom 2 .4 
Argentina 2 .4 
Italy 1 .2 
Mexico 1 .2 
South Africa 1 .2 
Venezuela 1 .2 
Colombia 1 .2 
Indonesia 1 .2 
No Response 18 4 
   
Level of education    
Less than high school 1 .2 
High school diploma 32 7.1 
Technical School/Some college 104 23 
College graduate 189 41.8 
Master’s degree 103 22.8 
Specialist or Ed.S. Degree 2 .4 
Doctorate 17 3.8 
No response 4 .9 
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Table 1, Continued 
 
 Mean SD 
Mean Age 41.58 8.07 
Combined Family Income 89106.66 61601.88 
 
Procedures 
Prior to conducting this study, the researcher obtained permission to work with 
human participants from the Texas A&M Institutional Review Board (IRB).  The 
questionnaire was entered into SurveyMonkey® and assigned a URL for access.  
Invitations to participate were then sent to approximately 800 support groups for parents 
of children with autism.  Email addresses were obtained by searching for parent support 
groups on the websites autismspeaks.org and autism-society.org.   All data was recorded 
anonymously by SurveyMonkey®, with a respondent number attached to the data, and 
the data then extracted into SPSS from SurveyMonkey®.   
Measures  
A questionnaire was developed by the researcher and reviewed by members of 
the dissertation committee. On the questionnaire, participants were asked to complete 
questions regarding their use of and feelings toward different types of treatments, their 
perception of their child’s behavior, and demographic information.  The parent was also 
asked to indicate the severity of their child’s autistic behaviors on a line with end points 
of Mild to Severe.  This was intended to provide an indication of the parent’s 
perceptions of the severity of their child’s problems.  Codes were attached to the data as 
it was entered into Survey Monkey ™, so that it was not be identifiable in the data base.  
A copy of the questionnaire is provided in Appendix A.   
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Data Analyses 
All data were checked prior to beginning the analyses.  In some instances, the 
data as provided by SurveyMonkey® needed to be aggregated to create variables for 
analysis. As will be seen in Chapter IV, the analyses included frequency counts, 
descriptive information (means and standard deviations), correlations, and regression.  
The data are sufficient to address the questions with the sample size obtained. 
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CHAPTER IV 
RESULTS 
 This chapter provides the results of the analyses.  Data from the survey were 
transformed into SPSS and any aggregate variables needed were created.  The results are 
presented by research question as follows: 
1. Do parents of children with an ASD who exhibit more severe behavioral symptoms 
gravitate toward complementary and alternative (CAM) treatments and therapies? To 
what extent does severity predict the number of CAMs ever used?   
 It is not known the extent to which severity is associated with individual CAM 
treatments. It was hypothesized that parents of children with more severe behavioral 
symptoms would seek out more complementary and alternative treatments and therapies. 
To address this question, the frequencies for individual CAMs, as well as total CAMs 
used or currently using were determined.  Two-way correlational analysis was then 
conducted to determine the level of relationship between the use of specific CAMs with 
severity as indicated by distance on the severity line on the questionnaire.  Results are 
presented in Table 2.  In addition, regression was used to test the hypothesis that severity 
would predict the total number of CAMs used (see Table 3). 
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Table 2  Treatment by Severity Correlations 
 
 
Treatment 
Severity 
Tried in the Past Currently Using 
Gluten-Free/Casein-Free (GFCF) 
Diet 
.16*** -.03 
Specific Carbohydrate diet .09* .06 
Digestive enzymes .06 -.02 
Probiotics .13** -.06 
Antifungals .08 .07 
Antibiotics -.01 .07 
D-Cycloserine --- --- 
Intravenous Immunoglobulin .09 .05 
Secretin .21*** .02 
Dimethylglycine .08 .01 
Omega-3 Fatty acid supplements .16*** -.10* 
Tryptophan .06 -.02 
Tyrosine -.001 .02 
Cypropheptadine -.08 .08 
Naltrexone -.02 .01 
SAM-E (S-adenosylmethionine) .12* .05 
Oxytocin infusion -.02 -.07 
Hyperbaric oxygen therapy .06 -.002 
Vitamin C .03 -.01 
Melatonin .10* .11* 
St. John’s wort .04 .05 
Vitamin B12 .06 -.01 
Glutathione .12** -.05 
Vitamin B6 and magnesium .09 .01 
Folic acid .09 .02 
Metallothionein .07 -.04 
Chelation .07 -.04 
Auditory integration training .04 -.04 
Sensory integration therapy .001 .10* 
Massage therapy .04 .01 
Craniosacral manipulation .07 -.003 
Facilitated communication .08 .13** 
Music therapy .09 .03 
Behavioral optometry .03 .01 
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 Results indicated a statistically significant relationship between severity of 
symptoms with having tried treatments in the past, and with currently using treatments.  
Treatments tried in the past that were correlated with greater severity of symptoms 
included: Gluten-Free/Casein-Free diet (.16,  p ≤ .001), Secretin (.21, p ≤ .001), Omega-
3 Fatty acid supplements (.16, p ≤ .001), Probiotics (.13, p ≤.01), Glutathione (.12, p 
≤.01), Specific Carbohydrate diet (.09, p ≤.05), SAM-E (S-adenosylmethionine) (.12, p 
≤.05), and Melatonin (.10, p ≤.05).  Treatments that were currently being used that were 
correlated with greater severity of symptoms included: Facilitated Communication (.13, 
p ≤.01), Melatonin, (.11, p ≤.05), and Sensory integration therapy (.10, p ≤.05).  
Interestingly, current use of Omega-3 Fatty Acid supplements (-.10 , p ≤.05) had a 
negative relationship with severity of symptoms, while previous use of Omega-3 was 
positively correlated with greater severity of symptoms.  In addition, it was noted that no 
one endorsed ever having used D-Cycloserine.  Severity of symptoms was not predictive 
of the total number of CAMs used. 
 
Table 3  Regression for Severity and CAM Use 
Variable B SE B β t Sig. 
Total Number 
of CAMs Ever 
Used 
.313 .113 .131 2.779 .006 
 Note. R2 = .017; Adjusted R2 = .015; CI for β = .092 to .535 
 
2. To what extent does demographic information of the parents affect their treatment 
decision for their child with an ASD?  
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 It was hypothesized that parent characteristics (e.g., marital status, country of 
origin, length of time in the United States, educational level, and employment status) 
will have an impact on their use of CAM. To address this question, regression was used.  
Variables of marital status, country of origin, educational level, and employment status 
were coded and used as independent variables.  Country of origin was collapsed to two 
groups – born in the U.S. or not born in the U.S., due to the number of differing 
countries of origin. Educational level was also collapsed into 5 groups: less than high 
school, high school diploma, technical school/some college, college graduate, and 
graduate level degree.  The total number of CAMs used was entered as the dependent 
variable. Results are presented in Table 4.  
 
Table 4  Demographic Variables as Predictors of CAM Use 
Variable B SE Β t Sig. 
Marital Status -1.24 .61 -.1 -2.02 .04 
Country of Origin -.83 1.11 -.04 -.75 .45 
Educational Level 1 .3 .16 3.39 .001 
Ethnicity -.1 .1 -.05 -.93 .35 
Note. F (4, 435) = 3.98, p = .003 
 
 Based on the multivariate regression, educational level ( p ≤ .001) and marital 
status (p ≤.05) were predictive of CAM use.  In order to better understand the ways in 
which marital status and educational level were predictive CAM use, Analysis of 
Variance was used.  Results are presented in Table 5 and Table 6. 
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Table 5  Analysis of Variance – Marital Status 
Variable N Mean Standard Deviation F p 
Single 16 4.5 4.13   
Married 384 6.4 5.8 
Divorced 40 3.8 3.35 
Widowed 9 3.89 2.42 
Total 449 6.06 5.59 3.62 .01 
 
Table 6  Analysis of Variance – Educational Level 
Variable N Mean Standard 
Deviation 
F p 
High School Diploma 32 4.47 5.38   
Technical School/Some College 104 4.85 4.58 
College Graduate 189 6.45 5.47 
Graduate level degree 122 6.96 6.3 
Total 447 6.07 5.57 3.95 .008 
 
 No interaction effect was found (p=.76).  Results of a Tukey analysis indicated 
that individuals with a graduate level degree were much more likely (p=.002) to use 
CAM than those with technical school/some college.  In addition, respondents who were 
married were significantly more likely to use CAMs than those who were divorced 
(p=.05).   
3. Are there specific characteristics of the CAM treatments that impact decision-
making (e.g., cost, accessibility, the number of available treatments, research base, 
treatment acceptability)?   
It was hypothesized that specific characteristics of CAM treatments would 
impact decision-making.  As with Question 2, regression was used to determine the 
extent to which these factors impact on the use of CAM treatments.  Cost, accessibility, 
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availability, research base, and acceptability were all coded and entered as independent 
variables. Total number of CAM treatments was the independent variable.  Results are 
provided in Table 7. These results indicate that accessibility (p ≤.05) and acceptance (p 
≤.05) were predictive of CAM use.   
 
Table 7  CAM Characteristics as Predictors of CAM Use 
Variable B SE β t Sig. 
Cost -.31 .26 -.06 -1.20 .23 
Accessibility .64 .31 .12 2.06 .04 
Research .48 .32 .09 1.51 .13 
Side effects -.47 .33 -.86 -1.44 .15 
Difficulty .40 .33 .07 1.22 .22 
Acceptance .77 .32 .14 2.41 .02 
         Note. F (6, 429) = 5.54, p < .001 
 
4. What are some of the barriers to treatment (belief that Autism is/is not curable, ease 
of obtaining information, number of medical professionals consulted, and experience 
with health care system)?   
It was hypothesized that there would be multiple barriers to treatment.  Results 
for each of these potential barriers were calculated and are presented in Table 8.  Based 
on responses, 78.1% of respondents indicated a belief that autism was not curable, while 
20.1% indicated a belief that autism is curable.  When asked to rate the level of difficulty 
to obtain information about treatments, a majority of respondents (42.5%) indicated that 
it is “somewhat hard” to obtain information, while 25.9% indicated that it is “not hard” 
to obtain information, 17.9% indicated that it is “hard” to obtain information, 8% 
indicated that it is “very hard” to obtain information, and 5.1% indicated that it is 
“extremely hard” to obtain information.   
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Regarding overall experience with the healthcare system, a majority (39.8%) 
indicated having had a “good” overall experience.  29% of respondents indicated a “bad” 
overall experience, and 13.1% indicated a “very bad” experience.  15% indicated a “very 
good” experience, and 1.8% indicated an “extremely good” experience.  In addition, the 
respondents indicated consulting with an average number of 4.1 medical professionals 
(SD = 5.89) when seeking a diagnosis for their child. 
 
Table 8  Barriers to Treatment 
 Frequencies Percent 
Belief that autism is not 
curable 
353 78.1 
Belief that autism is curable 91 20.1 
No response 8 1.8 
   
Obtaining information 
about treatments is: 
  
Not hard 117 25.9 
Somewhat hard 192 42.5 
Hard 81 17.9 
Very hard 36 8 
Extremely hard 23 5.1 
No response 3 .7 
   
Overall Experience with 
healthcare system: 
  
Extremely good 8 1.8 
Very good 68 15 
Good 180 39.8 
Bad 131 29 
Very bad 59 13.1 
No response 6 1.3 
  
 Mean SD 
Number of Professionals 
Consulted 
 
4.1 
 
5.89 
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Supplemental Information 
 Two questions on the survey were open-ended.  There were 258 responses to the 
question, “Have you tried any treatments that are not listed above?”  Parents endorsed 
several treatments that were not listed in the survey, and they also included treatments 
that are not considered CAMs.  Several medications were endorsed, including: Abilify, 
Prozac, Ritalin, Vyvanse, Risperidone, Risperidol, Lexapro, Zoloft, Stratterea, Adderall, 
Celexa, Concerta, Intuniv, Clonidine, Aricept, Metroprolol, and Focalin.  Medical 
marijuana and Respen-A were also endorsed as a treatments.  In addition, supplements 
and vitamins such as Vitamins C, D, and E, Iron, Zinc, Enhansa (curcumin supplement), 
Ecchinacea, Inositol, Syndion, rhodiola, Agrisept-L (citrus seed extract) and olive leaf 
extract were endorsed.   
 Different types of diets were also endorsed.  These included: the Feingold diet, 
the “rotation” diet, the “Body Ecology” diet, diets free of artificial preservatives, soy, 
lactose, corn products, MSG, yeast, and organic diets.  Taking baths with Epsom salts 
was also endorsed as a treatment.  Several parents endorsed using behavior modification 
techniques and programs, such as Applied Behavior Analysis, the Lovaas method, 
TEACCH, and Floortime.  Speech therapy, occupational therapy, and physical therapy 
were endorsed as treatments. 
 Parents also indicated that their children participated in different types of 
counseling (e.g., cognitive-behavioral therapy, “talk therapy,” “therapeutic listening,” 
“hypno-therapy” “emotional development therapy”) and social skills groups.  Some 
other treatments endorsed were “joint compressions,” reflexology, acupuncture, 
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aromatherapy, yoga, “brushing,” hippotherapy, equine therapy, dolphin therapy, and 
“foot zoning.”  Reiki, which according to Hyman and Levy (2010) is “…a form of 
spiritual healing in which the practitioner channels “universal life energy” to the 
recipient through light touch,” (p. 287) was also endorsed.  Several parents indicated that 
they considered using “toxin-free” products in the home (e.g., shampoo, laundry 
detergent) as a type of treatment.  Finally, Heilkunst, Nambudripad’s Allergy 
Elimination Techniques (NAET), Sound and Light Therapy, Neurofeedback, Oxidative 
stress relief were indicated. 
 A total of 426 people responded to the question, “What behaviors most concern 
you about your child?”  Several respondents described maladaptive behaviors as most 
concerning.  These were described as temper tantrums, meltdowns, outbursts, fits, and 
rages; behaviors that involved screaming; behaviors that were aggressive or violent.  
Physical aggression (e.g., hitting, biting, and clawing) and self-injurious behaviors (e.g., 
head-banging, biting oneself) were also endorsed as main areas of concern.  Several 
parents indicated concerns that their children lack “common sense” or do not have a 
sense of “personal safety,” which often causes them to be in dangerous situations (e.g., 
running into the street).  Oppositional Defiant Disorder (ODD) was specifically 
mentioned, as well as Obsessive-Compulsive Disorder (OCD).  Sexually inappropriate 
behaviors (e.g., making inappropriate comments, touching other people, masturbating in 
public) were listed as a main area of concern as well. 
 Not surprisingly, several respondents indicated several areas of communication 
as most concerning.  Difficulties with speech (including being non-verbal), speech 
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development delays, echolalia, functional communication, and understanding pragmatics 
(casual conversation) were listed as main areas of concern.  Their child’s difficulties 
with nonverbal communication were also endorsed as a main area of concern.  Also 
related to behaviors in the diagnostic criteria, repetitive, ritualistic, and stereotypical 
behaviors (e.g., arm flapping) were endorsed.   In the academic domain, parents 
endorsed difficulties with learning, including reading and writing disabilities, as main 
areas of concern.  Fine and gross motor skills were also a major area of concern.  Social 
skills were also endorsed as a main area of concern.  Parents indicated that their children 
have a lack of awareness of others, difficulty with empathy, and difficulty understanding 
others’ points of view.  The ability to make friends, relate to peers, and a lack of desire 
to make friends or interact with other children were also areas that were endorsed as 
areas of concern.  Parents of older children on the spectrum also had some specific 
concerns.  One parent of a college student with an ASD mentioned that difficulties 
understanding subtleties of social interactions with fellow students and professors was 
her biggest concern.  In addition, other parents of older children endorsed “lack of a 
social life” as their biggest concern.  Navigating the social demands of holding a regular 
job after high school, the ability to be self-sufficient and manage one’s own finances, 
were also endorsed as areas of concern.  One parent expressed concern that their child is 
“easily taken advantage of,” due to difficulty understanding social norms.  Difficulties 
with transitions or changes in routine, rigidity, and “black and white” thinking were 
endorsed as areas of concern.   In addition, having a limited range of interests, or 
perseverating on “strange topics or ideas” was listed as a main area of concern. 
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 Potentially related to the choices for CAM treatments, sensory behaviors, such as 
“stimming,” biting and mouthing objects, and hypersensitivity to sounds were frequent.  
Concerns about stimming behaviors were often related to issues of safety.  For example, 
one parent said that their child enjoyed staring into bright light (including the sun).  
Feeding disorders (e.g., Pica), as well as their children having a limited diet due to being 
aversive to sensory aspects of some foods (e.g., texture) were concern for some parents.  
Heightened sensitivity to sensory input was also listed as a concern.  
 Emotional concerns, such as depression, anxiety, and self-esteem, were endorsed 
by some parents.  Attention-Deficit Hyperactivity Disorder (ADHD) was specifically 
endorsed as a concern by several parents.  In addition, symptoms related to ADHD (e.g., 
inattention, hyperactivity, impulsivity) were often mentioned.  Difficulties with sleep 
(e.g., abnormal sleep patterns) were endorsed by some parents as were gastrointestinal 
difficulties (e.g., bowel discomfort) and toilet training. Notably, one parent endorsed 
having a child who was “recovered,” saying that the child had “lost his diagnosis and 
shows no signs of autism.” 
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CHAPTER V 
 
CONCLUSIONS 
 The purpose of this study was to examine factors that contribute to parents’ 
decisions to treat their child with ASD using a complementary or alternative treatment.  
In order to determine this, an online survey was developed, and invitations to participate 
were sent to approximately 800 support groups for parents of children with autism.  
Results from 452 respondents indicated that a statistically significant relationship existed 
between severity of symptoms with having tried treatments in the past, as well as with 
currently using treatments.   
 Overall, the responding parents/guardians were mothers, fathers, and 
grandmothers with a mean age of 41.58.  The majority self-identified as White (86.7%), 
with a majority having attained a college education (41.8%) and of moderate income 
($89,106.66).  100% of the participants in the study indicated they had tried a CAM in 
the past, or were currently using one.   
Severity and CAM Treatment 
 Treatments tried in the past that were correlated with greater severity of 
symptoms included: Gluten-Free/Casein-Free diet, Secretin, Omega-3 Fatty acid 
supplements, Probiotics, Glutathione, Specific Carbohydrate diet, SAM-E (S-
adenosylmethionine), and Melatonin.  Treatments that were currently being used that 
were correlated with greater severity of symptoms included: Facilitated Communication, 
Melatonin, and Sensory integration therapy.   
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Socioeconomic and Educational Level 
 Educational level and marital status were found to be predictive of CAM use.  
Specifically, individuals who were married were more likely to use CAMs than those 
who were divorced.  In addition, individuals who endorsed having attained a graduate 
level degree were more likely to report use of CAMs with their children than those 
having attained an educational level of technical school/some college.   
CAM Characteristics 
 Although when taken together characteristics of treatments themselves are not 
predictive of CAM use, results indicate that accessibility of treatments and the child’s 
acceptance of the treatments were predictive of CAM use.   
Barriers to Treatment 
As an initial barrier, 78.1% of respondents indicated a belief that autism is not 
curable. When asked to rate the level of difficulty to obtain information about 
treatments, a majority of respondents (42.5%) indicated that it is “somewhat hard” to 
obtain information.  Regarding overall experience with the healthcare system, a majority 
(39.8%) indicated having had a “good” overall experience.  At the same time, however, 
the respondents indicated consulting with an average number of 4.1 medical 
professionals when seeking a diagnosis for their child.   
Other Treatment Approaches 
 When asked about other treatment approaches that were not listed on the survey, 
parents endorsed several treatments that would also be considered CAM treatments (e.g., 
dolphin therapy, Reiki), as well as treatments that are considered conventional (e.g., 
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medications, Applied Behavior Analysis).  Several medications, supplements, and 
vitamins were endorsed.  Different types of diets, counseling, and therapies based on 
behavior modification techniques were also endorsed.  Some parents also endorsed the 
use of “toxin-free” products in the home as a type of treatment. 
Limitations 
 There are several limitations to this study.  The survey was only available online, 
so individuals without access to a computer were unable to complete the study.  
Recruitment was extensive, but it is not possible to determine a return rate, furthering the 
possibility of selection bias.  No control for severity or recency of diagnosis was 
included.   
Conclusions and Future Directions for Research 
 Every parent who participated in this study indicated that they had either tried a 
CAM treatment in the past, or were currently using a CAM treatment with their child 
with ASD.  Married parents endorsed more use of CAM treatments than divorced 
parents.  In addition, individuals with graduate level degrees endorsed more use of CAM 
treatments than those with technical school/some college. Several reasons for these 
findings can be hypothesized.  Individuals who are married possibly benefit from mutual 
support from one another when seeking out treatments that are considered alternative.  It 
may be informative for future researchers to seek more detailed information regarding 
marital status (e.g., whether an individual who endorses himself or herself as currently  
“married” is with the child’s other biological parent).  Regarding educational level, 
individuals with higher levels of education are possibly more comfortable seeking out 
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alternative sources of information, and are more comfortable seeking out multiple 
professional opinions.   
 When asked to give information regarding other treatment approaches that were 
being used that were not listed on the survey, parents endorsed some different treatments 
that would be considered complementary and alternative (e.g., dolphin therapy), and also 
listed treatments that are considered to be conventional (e.g., medications, therapies 
based on behavioral principles). Regarding behaviors considered most concerning, 
parents described physically aggressive behaviors and self-injurious behaviors as main 
areas of concern.  Concerns about personal safety, sexually inappropriate behaviors, 
communication, academics, social skills, and emotionality (e.g., anxiety and depression) 
were also endorsed.  Overall, it appears that a combination of individual characteristics 
of parents, as well as characteristics of the treatments, influence treatment decisions. 
 The findings of this study are important for a number of reasons.  As has been 
shown, use of CAM treatments is growing among the population of children with 
autism.  However, information regarding the reasons parents decide to use these 
treatments with their children is relatively sparse.  In addition, while research has shown 
some promising results regarding use of some treatments, further information regarding 
their usefulness is needed before they are recommended (Zimmer & Molloy, 2007; 
Zimmer, 2011).  In addition, while many parents endorsed using different types of 
animal therapies (e.g., dolphin therapy, equine therapy) with their children, these 
methods are generally not included in literature regarding CAM treatments with children 
with autism.  Further investigation into these therapies is warranted, as many families 
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appear to seek out these therapies and regard them as treatments.  As many CAM 
treatments are being used, methodologically sound research regarding efficacy and 
safety of these treatments is needed.  The same type of random clinical trials for 
medications and evidence based practices should be in place for CAM treatments.  This 
would include (but is not limited to) taking into consideration the use of clear diagnostic 
criteria, sample size, control groups, and subject treatment status (Zimmer and Molloy, 
2007).   
 In addition, ways to educate and disseminate information to families making 
treatment decisions is needed. It will be important that medical professionals working 
with these families become well-versed in the different types of CAM treatments 
available, and are able to sensitively and clearly communicate information regarding 
these treatments.  Parents should be made aware of the extent and quality of research 
conducted on potential treatments, including possible side effects and safety concerns 
associated with the use of some treatments.  Professionals working with parents should 
also be able to use their knowledge of scientifically-based treatments when consulting 
with parents, and be able to recommend empirically-supported treatments.  
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APPENDIX A 
 
QUESTIONNAIRE 
 
Demographic information: 
 
Are you the child’s 
___Mother  
___Father   
 
Your Age: _____ 
 
Marriage status: 
___Single  
___Married 
___Divorced  
___Widowed  
 
Ethnicity: 
___White 
___Black or African American 
___American Indian and Alaska Native 
___Asian 
___Native Hawaiian or other Pacific Islander 
___Hispanic or Latino 
___Biracial 
___Other 
 
Level of Education: 
___Less than High School 
___High School Diploma 
___Technical School/Some College 
___College Graduate 
___Master’s Degree 
___Specialist or Ed.S. Degree 
___Doctorate 
 
How many children are in your family? 
 
___________ 
 
What country were you born in? 
 
__________________________________________________________________ 
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If you were not born in the United States, how long have you lived here? 
 
__________________________________________________________________ 
 
In what country have you lived most of your life? 
 
__________________________________________________________________ 
 
Combined family income (approximate): 
 
__________________________________________________________________ 
 
Treatment characteristics: 
 
Please mark on the line (/) how severe you consider your child’s behavioral symptoms to 
be. 
 
Mild          Severe 
_________________________________________________________________ 
 
 
Do you believe that autism is currently curable? 
 
___Yes 
___No  
 
When choosing a treatment, where do you get most of your information about the 
treatment? (Please indicate all sources you consider) 
_______________________________________________________________________
_ 
 
_______________________________________________________________________
_ 
 
_______________________________________________________________________
_ 
 
When choosing a treatment, do you seek treatments that will: 
___Cure autism 
___Reduce symptoms of autism 
 
How hard is it to obtain information about possible treatments for you child? 
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___Not hard 
___Somewhat hard 
___Hard 
___Very hard 
___Extremely hard 
 
When considering a treatment for your child, which of the following are important to 
you?  Please indicate importance by circling the following: 
 
1 – most important 
2 – very important 
3 – important 
4 – not very important 
5 – not at all important 
 
Cost of the treatment     1 2 3 4 5 
How easy it is to get access to the treatment  1 2 3 4 5 
Amount of research about the treatment  1 2 3 4 5 
Possible side effects of the treatment   1 2 3 4 5 
Difficulty of giving the treatment   1 2 3 4 5 
Child’s acceptance of the treatment   1 2 3 4 5 
 
 
Have you ever tried any of the following treatments for your child: 
 
Treatment                                                 Tried in the past                           Currently 
using 
Secretin………………………………………   __                 __ 
Gluten-free/Casein-free diet        
 (GFCF diet)………………………….   __              __ 
Specific Carbohydrate diet…………………..   __              __
  
Digestive enzymes…………………………...   __              __ 
Probiotics……………………………………..  __              __
  
Antifungals…………………………………...  __              __ 
Antibiotics……………………………………. __              __ 
D-Cycloserine………………………………...  __              __ 
Intravenous Immunoglobulin………………...  __              __ 
Dimethylglycine……………………………….__              __
  
Omega-3 Fatty acid supplements……………   __              __ 
Tryptophan…………………………………… __              __
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Tyrosine………………………………………. __              __ 
Cyproheptadine………………………………..__              __ 
Naltrexone……………………………………..__              __ 
SAM-E (S-adenosylmethionine)………………__              __ 
Oxytocin Infusion……………………………...__              __ 
Hyperbaric oxygen therapy…………………..  __              __ 
Vitamin C……………………………………...__              __ 
Melatonin………………………………………__              __ 
St. John’s wort…………………………………__               __ 
Vitamin B12………………………………….. __              __ 
Glutathione…………………………………….__               __ 
Vitamin B6 and magnesium…………………   __               __ 
Folic acid………………………………………__              __ 
Metallothionein……………………………….. __              __ 
Chelation……………………………………… __              __ 
Auditory integration training…………………..__              __ 
Sensory integration therapy……………………__              __ 
Massage therapy……………………………….__              __ 
Craniosacral manipulation……………………. __              __ 
Facilitated communication…………………… __              __ 
Music therapy………………………………….__              __ 
Behavioral optometry………………………….__              __ 
      
 
Have you tried any treatments that are not listed above?  Please list: 
 
Treatment   Tried in the past      Currently using 
______________   ___   ___ 
______________   ___   ___ 
______________   ___   ___ 
______________   ___   ___ 
______________   ___   ___ 
 
 
How many medical professionals (doctors, psychologists, etc.) have you visited in order 
to obtain a diagnosis for you child?  
____ 
 
Overall, how do you rank the quality of your experiences with the health care system 
when seeking treatment for you child? 
 
___Extremely good 
___Very good 
___Good 
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___Bad 
___Very Bad 
 
What behaviors most concern you about your child? 
 
 
 
Thank you for completing this questionnaire.  
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